1-7 of 7
Adam Idoine
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma

Free
Hang Quach, Rakesh Popat, Wenming Chen, Mary Kwok, Andrew Yee, Zhongxing Jiang, Flávia Xavier, Natalie Callander, Man Yuk Ho, Susan Bal, Michael Low, Douglas Sborov, Gabriel Man, Huan Cheng, Adam Idoine, Xin Wang, Amit Agarwal, Binod Dhakal
Journal: Blood
Blood (2025) 146 (Supplement 1): 102.
https://doi.org/10.1182/blood-2025-102
Published: 2025
Journal Articles

Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up

Free
Mazyar Shadman, Ian Flinn, Moshe Levy, Steven Papish, John M. Burke, Jamal Misleh, Jennifer Cultrera, Habte Yimer, Edwin Kingsley, Charles Farber, James D'Olimpio, Nan Sun, Adam Idoine, Jeff Sharman
Journal: Blood
Blood (2025) 146 (Supplement 1): 5663.
https://doi.org/10.1182/blood-2025-5663
Published: 2025
Journal Articles

Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

Free
Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Benjamin B. Freeman, Ben Zhang, John M. Burke, Jennifer L. Cultrera, Habte A. Yimer, Edwin C. Kingsley, Charles M. Farber, James D'Olimpio, Hui Yao, Adam Idoine, Qi An, Jeff P. Sharman
Journal: Blood
Blood (2024) 144 (Supplement 1): 4632.
https://doi.org/10.1182/blood-2024-198250
Published: 2024
Journal Articles

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Free
Mazyar Shadman, Ian W. Flinn, Edwin C. Kingsley, Benjamin B. Freeman, Moshe Levy, Charles M. Farber, James D'Olimpio, Jennifer L. Cultrera, Ben Zhang, Rocco J. Crescenzo, Adam Idoine, Xiaoping Zhang, Kunthel By, Jeff P. Sharman
Journal: Blood
Blood (2023) 142 (Supplement 1): 3279.
https://doi.org/10.1182/blood-2023-174096
Published: 2023
Journal Articles

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Free
Linlin Xu, Mazyar Shadman, Ian W. Flinn, Moshe Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte A. Yimer, Benjamin B. Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Rocco J. Crescenzo, Kunthel By, Aileen Cleary Cohen, Adam Idoine, Sudhir Manda, Jeff P. Sharman
Journal: Blood
Blood (2023) 142 (Supplement 1): 6510.
https://doi.org/10.1182/blood-2023-180161
Published: 2023
Journal Articles

Acquired Mutations in Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) That Progressed in the ALPINE Study

Free
Jennifer R. Brown, Jessica Li, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Luqui Qiu, Vanitha Ramakrishnan, Ruiqi Huang, Yang Shi, Adam Idoine, Tommi Salmi, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1890.
https://doi.org/10.1182/blood-2023-173547
Published: 2023
Journal Articles

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Free
Mazyar Shadman, Ian W. Flinn, Edwin C. Kingsley, Benjamin Freeman, Moshe Yair Levy, Houston Holmes, Charles M. Farber, Arvind Chaudhry, Rocco Crescenzo, Adam Idoine, Xiaoping Zhang, Aileen Cohen, Kunthel By, Jane Huang, Jeff P. Sharman
Journal: Blood
Blood (2022) 140 (Supplement 1): 3655–3657.
https://doi.org/10.1182/blood-2022-159726
Published: 2022